Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06302543
Other study ID # POI bone marrow
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2024
Est. completion date October 24, 2024

Study information

Verified date March 2024
Source Global Stem Cell Center, Baghdad
Contact abdulmajeed hammadi, MD
Phone +9647902268105
Email majeed51578@yahoo.co.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-Mullerian hormone. Autologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program.


Description:

Premature ovarian insufficiency is a clinical syndrome characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotrophin hormones and low estrogen and anti-Mullerian hormone. The average age for menopause is 50-52 years in the developed world ,it is believed that about 1% for women less than 40 years of age and 0.1 in less than 30 years of age has premature ovarian insufficiency. Etiology of POI may be genetic, chromosomal, or auto immune.in addition to cancer treatment and surgical causes. Hormonal replacement therapy is recommended for POI patients to alleviate vasomotor symptoms in addition to prevent osteoporosis and ischemic heart disease. Regenerative medicine is a new medical approach to treat variety of diseases involving many tissues or organs in human body using cells, biological products instead of drugs or physical factors. Autologous use of stem cells from bone marrow or adipose tissue (stromal vascular fraction) or platelet rich plasma are alternative safe minimal manipulative products that can provide a solution to this clinical syndrome. Only few cases had been mentioned in the literature offering autologous stem cells for treating POI including bone marrow or adipose derived stem cells in addition to mesenchymal stem cells expanded invitro. the investigator use autologous bone marrow concentrate with transvaginal approach under ultrasound guidance to treat POI.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date October 24, 2024
Est. primary completion date September 10, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: 1. clinical diagnosis of premature Ovarian insufficiency. 2. ineffective hormonal therapy. 3. biochemical evidence of high gonadotropins. Exclusion criteria: 1. solid or hematological malignancies. 2. bleeding disorders. 3. rejection of the procedure.

Study Design


Intervention

Procedure:
autologous bone marrow cells injection
under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection

Locations

Country Name City State
Iraq Ministry of Health Baghdad

Sponsors (1)

Lead Sponsor Collaborator
abdulmajeed hammadi

Country where clinical trial is conducted

Iraq, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in gonadotropin levels luteinizing hormone and follicular stimulating hormone are followed check every 4 weeks through study completion, an average of 1 year".
See also
  Status Clinical Trial Phase
Recruiting NCT06072794 - A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI) Phase 1
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Completed NCT04641624 - sFlt- 1, PIGF, and Niacin Levels in Women With Premature Ovarian Insufficiency
Recruiting NCT05308342 - Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency N/A
Not yet recruiting NCT06067529 - A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency
Recruiting NCT05665010 - Precise Stratification of Genetic Risk of Ovarian Function Impairment
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Completed NCT04475744 - 4-step ASCOT in POI Women to Promote Follicular Rescue Phase 3
Recruiting NCT05279560 - Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation N/A
Recruiting NCT06145061 - Evaluation on Biological Characteristics of Acupoints in Premature Ovarian Insufficiency
Recruiting NCT05858307 - Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
Completed NCT06228547 - Women's Experience of Premature Ovarian Insufficiency (POI) Diagnosis: Update on Actual Practices and Patient's Follow up
Recruiting NCT06102655 - Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics Early Phase 1
Recruiting NCT05485610 - Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency) N/A
Recruiting NCT05586737 - Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency Phase 2
Recruiting NCT04167033 - Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QT-IOP) N/A
Not yet recruiting NCT06339489 - The Bone Metabolism Characteristics of Premature Ovarian Insufficiency